Compare HCA Health Inc (HCA) vs Lam Research Corporation (LRCX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
HCA Health Inc vs Lam Research Corporation — how do they compare? HCA Health Inc trades at $371.15 (market cap $82.17B), while Lam Research Corporation trades at $318.35 (market cap $383.63B). The key difference: Lam Research Corporation is far larger — about 4.7× HCA Health Inc's market cap, and HCA Health Inc pays the higher dividend (0.84%). Which is the better fit depends on your goals.
| HCA | LRCX | |
|---|---|---|
Market Cap | $82.17B | $383.63B |
Sector | Health | Technology |
52-Week High | $545.13 | $433.33 |
52-Week Low | $334.32 | $94.84 |
Enterprise Value | $131.08B | $382.61B |
Dividend Yield | 0.84% | 0.34% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
HCA Healthcare trades at $370.74, down 0.12% on the day, with a bearish technical signal but strong fundamentals including consistent earnings beats and revenue growth to $75.6 billion in 2025. The stock faces headwinds from lowered 2026 guidance and negative news flow, but maintains a solid valuation with a P/E of 12.79 and positive analyst consensus.
The outlook is mixed: attractive valuation and operational strength support upside to the $469.40 price target, but near-term risks from payer mix shifts and legal investigations warrant caution. Long-term growth drivers include capacity expansion and medical advancements, though investor sentiment is currently pressured.
Lam Research (LRCX) trades at $306.96, down 2.02% amid semiconductor sector weakness. The stock shows strong fundamentals with Q1 2026 EPS beating estimates at $1.47 versus $1.36 expected, continuing a pattern of earnings outperformance. Valuation metrics remain elevated with P/E at 59.22 and P/S at 18.3, reflecting premium pricing for AI-driven growth prospects. Technical indicators show bearish momentum with price testing key support at $306.
Outlook remains positive based on analyst consensus with $393 price target (78% buy ratings), though near-term risks include semiconductor cycle volatility and rich valuations. The company's positioning in AI chip manufacturing equipment and strong cash flow generation ($6.17B operating cash flow in 2025) supports long-term growth potential despite sector headwinds.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About HCA Health Inc
HCA Healthcare is a Nashville-based healthcare provider organization operating the largest collection of acute-care hospitals in the U.S. As of December 2021, the firm owned and operated 182 hospitals, 125 freestanding outpatient surgery centers, and a broad network of physician offices, urgent care clinics, and freestanding emergency rooms across nearly 20 states and a small foothold in England.
Read more on HCA →About Lam Research Corporation
Lam Research manufactures equipment used to fabricate semiconductors. The firm is focused on the etching, deposition, and clean markets, which are key steps in the semiconductor manufacturing process, especially for 3D NAND flash storage, advanced DRAM, and leading-edge logic/foundry chipmakers. Lam's flagship Kiyo, Vector, and Sabre products are sold in all major geographies to key customers such as Samsung Electronics, Micron, Intel, and Taiwan Semiconductor Manufacturing.
Read more on LRCX →
